洛拉提尼布的营销后安全性:基于FDA不良事件报告系统的现实研究
Huqun Li1, Chongshu Wang2, Cuilian Guo2
1Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in pharmacology
|June 21, 2024
概括
这项研究分析了2,941份关于洛拉提尼布的不良事件报告,确定了诸如高胆固醇和等常见副作用. 它还标志着潜在的新风险,包括肺动脉高血压,对于形淋巴瘤激酶阳性非小细胞肺癌患者.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
背景情况:
- 洛拉提尼布在阳性形淋巴瘤激酶 (ALK) 非小细胞肺癌 (NSCLC) 中表现出显著的疗效.
- 确定洛拉提尼布的营销后安全性概况对于临床实践至关重要.
研究的目的:
- 使用食品和药物管理局的不良事件报告系统 (FAERS) 确定洛拉提尼布的安全概况.
- 通过不成比例性分析,识别与洛拉提尼布相关的潜在不良事件 (AE).
主要方法:
- 对2019年至2023年的FAERS数据进行了不成比例分析.
- 报告几率比率 (ROR) 用于检测洛拉提尼布相关的副作用.
- 研究了AEs的临床特征,人口统计和发病时间.
主要成果:
- 在8,818,870份报告中,发现了2,941份与洛拉提尼布相关的AE报告.
- 检测到167个与lorlatinib相关的AE信号,高胆固醇血症,和认知障碍是常见的.
- 新的潜在副作用,如肺动脉高血压和辐射亡,需要进一步关注,以及评估间歇性肺病和AV阻塞.
结论:
- 这项研究提供了有关洛拉提尼布营销后安全性的见解,有助于合理的临床使用.
- 建议进行进一步的前性研究,以验证已识别的拉提尼布-AE关联.
相关概念视频
Pharmacovigilance
821
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
821
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
Antiasthma Drugs: Leukotriene Modifiers
274
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
274
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K


